FREMONT, Calif., Feb. 2, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and renal diseases, today announced that
Mike Raab, President and Chief
Executive Officer, and David
Rosenbaum, Ph.D., Senior Vice President of Drug Development,
will participate in the 2016 Leerink Partners Global Healthcare
Conference at 3:05 p.m. EST on
Wednesday, February 10, 2016 at the
Waldorf Astoria in New York
City.
The analyst-led fireside chat will be available through a live
audio webcast accessible through a link in the Investor Relations
section of the Ardelyx website at ir.ardelyx.com. A replay of
the webcast will be available for 30 days on the Company's website
after the presentation.
About Ardelyx
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal tract to treat gastrointestinal
and cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
constipation-predominant irritable bowel syndrome, or IBS-C, and
management of hyperphosphatemia in patients with end stage renal
disease. In addition to tenapanor, Ardelyx is developing RDX022, a
non-absorbed polymer for the treatment of hyperkalemia, or high
potassium, in kidney and heart disease patients. Ardelyx is also
advancing several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located in Fremont, California.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-2016-leerink-partners-global-healthcare-conference-300213976.html
SOURCE ARDELYX